Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 454-457

  Tateishi, Tomonori ^a   Kumai, Toshio ^a   Watanabe, Minoru ^a   Nakura, Hironori ^a   Tanaka, Masami ^a   Kobayashi, Shinichi ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP2C19; CYP3A; Drug interaction; Omeprazole; Ticlopidine

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 2C19; OMEPRAZOLE; STOMACH SECRETION INHIBITOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0032945411     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00914.x     Document Type: Article

References (21)

1. 1 McTavish D, Faulds D, Goa KL. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-259.
2. 2 Hass WK, Easton JD, Adams HP, Jr et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507.
3. 3 Desager J-P. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994; 26: 347-355.
4. 4 Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance: a case report. Neurology 1996; 46: 1172-1173.
5. 5 Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidine-phenytoin interaction. Arch Neurol 1996; 53: 1191-1192.
6. 6 Rindon JP, Bryan GII, Ariz P. Phenytoin toxicity associated with ticlopidine administration [letter]. Arch Intern Med 1996; 156: 1113.
7. 7 Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome-P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
8. 8 Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4′-hydroxylation of phenytoin: relationship to (S) mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997; 43: 441-445.
9. 9 Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17: 33-38.
10. 10 Karninsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
11. 11 Donahue SR, Flockhart DA, Abernethy DR, Ko J W. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther 1997; 62: 572-577.
12. 12 Guengerich FP. Human cytochrome P450 enzymes. In: Cytochrome P450, ed Oritiz de Montellano PR, New York: Plenum Press, 1995: 473-535.
13. 13 Andersson T, Miners J O, Tassaneeyakul W, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
14. 14 de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
15. 15 Kobayashi K, Chiba K, Sohn D-R, Kato Y, Ishizaki T. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline resistant polymer-coated C18 column. J Chromatogr 1992; 579: 299-305.
16. 16 Bertilsson L, Tybring G, Widén J, Chang M, Tomson T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997; 44: 186-189.
17. 17 Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolsim. Br J Clin Pharmacol 1994; 37: 597-604.
18. 18 Sohn D R, Kobayashi K, Hiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S mephenytoin 4′-hydroxylation recruited from an oriental population. J Pharmacol Exp Ther 1992; 262: 1195-1202.
19. 19 Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-747.
20. 20 Guengerirh FP. Roles of cytochrome P450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 1988; 48: 2946-2954.
21. 21 Goldstein JA, de Morais. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4: 285-299.